AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10091916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinse A
Number of subjects: 109
Study 10091916 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinse B
Number of subjects: 109
Study 10091916 — intervention group
Group type: COMPARATOR
Intervention: Control mouth rinse
Number of subjects: 109
Study 9550353 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline (500 mg daily for 10 days every six months)
Number of subjects: 45
Study 9550353 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline plus one hour of occlusion daily
Number of subjects: 45
Study 9550353 — intervention group
Group type: COMPARATOR
Intervention: One hour of occlusion daily
Number of subjects: 45
Study 1835334 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus two preoperative and three postoperative intralesional injections of triamcinolone
Number of subjects: 36
Study 1835334 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus oral colchicine (1.2 mg per day) initiated 3 weeks after surgery and continued for 5 months
Number of subjects: 36
Study 7027655 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Clobetasol-17-propionate
Number of subjects: 90
Study 7027655 — intervention group
Group type: COMPARATOR
Intervention: Other topical corticoids
Number of subjects: 90
Study 30956265 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 0
Study 30956265 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study 28793974 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK561679 (CRF1 receptor antagonist)
Number of subjects: 128
Study 28793974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 25855926 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary kallidinogenase (0.15 PNAU/d, for 7 days) after rt‐PA (0.9 mg/kg)
Number of subjects: 200
Study 25855926 — intervention group
Group type: COMPARATOR
Intervention: Control group received rt‐PA (0.9 mg/kg)
Number of subjects: 200
Study 23835501 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate circumcision
Number of subjects: 2784
Study 23835501 — intervention group
Group type: COMPARATOR
Intervention: Control (uncircumcised)
Number of subjects: 2784
Study 22092206 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope videolaryngoscope (GS)
Number of subjects: 100
Study 22092206 — intervention group
Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope (DL)
Number of subjects: 100
Study 19461530 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-Day Physical Activity Recall (7-Day PAR)
Number of subjects: 139
Study 19461530 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer
Number of subjects: 139
Study 17201542 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exclusion manipulation (participants told they would end up alone or were rejected by others)
Number of subjects: 7
Study 17201542 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exclusion manipulation
Number of subjects: 7
Study 15173773 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation-corrected studies using a gender-independent normal database
Number of subjects: 95
Study 15173773 — intervention group
Group type: COMPARATOR
Intervention: Conventional reconstruction and gender-specific database quantification
Number of subjects: 95
Study 11703991 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 0
Study 11703991 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (0.75 dose)
Number of subjects: 0
Study 11703991 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (0.5 dose)
Number of subjects: 0
Study 11703991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9743925 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 2 U/ml saline flush solution
Number of subjects: 90
Study 9743925 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 10 U/ml saline flush solution
Number of subjects: 90
Study 9743925 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline flush solution
Number of subjects: 90
Study 7818628 — intervention group
Group type: EXPERIMENTAL
Intervention: Bougie dilatation
Number of subjects: 93
Study 7818628 — intervention group
Group type: COMPARATOR
Intervention: Balloon dilatation
Number of subjects: 93
Study 3337087 — intervention group
Group type: COMPARATOR
Intervention: First vaccination (first vac)
Number of subjects: 3
Study 3337087 — intervention group
Group type: COMPARATOR
Intervention: Two or more recent vaccinations (multivac)
Number of subjects: 3
Study 31027051 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelidium elegans (1g)
Number of subjects: 100
Study 28306531 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-physiotherapy
Number of subjects: 61
Study 28306531 — intervention group
Group type: COMPARATOR
Intervention: Sham micro-physiotherapy
Number of subjects: 61
Study 25691237 — intervention group
Group type: EXPERIMENTAL
Intervention: Three‐minute video describing CPR and intubation plus verbal communication of participants' preferences to their physicians
Number of subjects: 150
Study 23759263 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg ALA-P plus 1.8 mg iron
Number of subjects: 212
Study 23759263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 21039672 — intervention group
Group type: EXPERIMENTAL
Intervention: Velusetrag 15 mg
Number of subjects: 0
Study 21039672 — intervention group
Group type: EXPERIMENTAL
Intervention: Velusetrag 30 mg
Number of subjects: 0
Study 21039672 — intervention group
Group type: EXPERIMENTAL
Intervention: Velusetrag 50 mg
Number of subjects: 0
Study 21039672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18391135 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 107
Study 18391135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.50 mg)
Number of subjects: 107
Study 18391135 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of naltrexone and ondansetron
Number of subjects: 107
Study 18391135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 16670166 — intervention group
Group type: EXPERIMENTAL
Intervention: T(4)‐T(3) combination therapy
Number of subjects: 1216
Study 14581402 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced periodic breathing
Number of subjects: 40
Study 14581402 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe HF
Number of subjects: 40
Study 14581402 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate HF
Number of subjects: 40
Study 14581402 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 40
Study 14581402 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic breathing, severe HF, and moderate HF
Number of subjects: 40
Study 14581402 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic breathing
Number of subjects: 40
Study 11093363 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone (8 mg/day to 32 mg/day)
Number of subjects: 3300
Study 11093363 — intervention group
Group type: COMPARATOR
Intervention: Iloperidone (compared with haloperidol)
Number of subjects: 3300
Study 11093363 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 3300
Study 8818856 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day azithromycin
Number of subjects: 0
Study 8818856 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day azithromycin
Number of subjects: 0
Study 8818856 — intervention group
Group type: COMPARATOR
Intervention: 10-day roxithromycin
Number of subjects: 0
Study 8818856 — intervention group
Group type: EXPERIMENTAL
Intervention: azithromycin
Number of subjects: 0
Study 1433880 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with droperidol, fentanyl and ketamine (DFK)
Number of subjects: 36
Study 2987601 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg megestrol acetate (MA)
Number of subjects: 33
Study 2987601 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg megestrol acetate (MA)
Number of subjects: 33
Study 2987601 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg megestrol acetate (MA)
Number of subjects: 33
Study 2987601 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg megestrol acetate (MA)
Number of subjects: 33
Study 2987601 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA) equivalent dosages 1000-1500 mg
Number of subjects: 33
Study 31173362 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin
Number of subjects: 577
Study 31173362 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 577
Study 30031803 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback Group (FG)
Number of subjects: 44
Study 30031803 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 44
Study 26368836 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 55
Study 26368836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 55
Study 24576857 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) supplementation (1200 mg·d)
Number of subjects: 10
Study 24576857 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) supplementation
Number of subjects: 10
Study 23114133 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly diagnosed group (19 patients)
Number of subjects: 46
Study 23114133 — intervention group
Group type: COMPARATOR
Intervention: Stable group (17 patients)
Number of subjects: 46
Study 20195124 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacustimulation (ReliefBand) and pharmacologic measures
Number of subjects: 122
Study 20195124 — intervention group
Group type: COMPARATOR
Intervention: Standardized pharmacologic postoperative nausea and vomiting prevention
Number of subjects: 122
Study 20195124 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacustimulation (ReliefBand)
Number of subjects: 122
Study 18076534 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant (AD) treatment
Number of subjects: 123
Study 18076534 — intervention group
Group type: COMPARATOR
Intervention: No Antidepressant (non-users)
Number of subjects: 123
Study 16789520 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring System (CGMS)
Number of subjects: 60
Study 12625847 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (PDE5 inhibitor)
Number of subjects: 0
Study 12625847 — intervention group
Group type: COMPARATOR
Intervention: Nitrates
Number of subjects: 0
Study 10480613 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)‐monomethyl‐L‐arginine (L‐NMMA); total dose 5 mg/kg body weight
Number of subjects: 7
Study 10480613 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study 10480613 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arginine (5 mg/kg body weight) co-infused during the final 5 min of each exercise bout
Number of subjects: 7
Study 9592304 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (Cla) 500 mg b.i.d and Furazolidone (Fur) 200 mg b.i.d plus CBS 240 mg b.i.d (group I A)
Number of subjects: 88
Study 9592304 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (Cla) 500 mg b.i.d and Furazolidone (Fur) 200 mg b.i.d plus Lan 30 mg b.i.d (group I B)
Number of subjects: 88
Study 9592304 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (Cla) 250 mg b.i.d and Furazolidone (Fur) 100 mg b.i.d plus CBS 240 mg b.i.d (group II A)
Number of subjects: 88
Study 9592304 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (Cla) 250 mg b.i.d and Furazolidone (Fur) 100 mg b.i.d plus Lan 30 mg q.d (group II B)
Number of subjects: 88
Study 9592304 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase one study (all groups)
Number of subjects: 88
Study 9592304 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase two study (all groups)
Number of subjects: 88
Study 9592304 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (Cla) resistance
Number of subjects: 88
Study 2063703 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva samples returned by mail
Number of subjects: 0
Study 2063703 — intervention group
Group type: COMPARATOR
Intervention: Saliva samples returned by interviewers
Number of subjects: 0
Study 6138642 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIG plus hepatitis B vaccine
Number of subjects: 159
Study 6138642 — intervention group
Group type: COMPARATOR
Intervention: HBIG alone
Number of subjects: 159
Study 6138642 — intervention group
Group type: COMPARATOR
Intervention: Vaccination alone
Number of subjects: 159
Study 6138642 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 159
Study 30452284 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIex (High-Intensity Interval Exercise)
Number of subjects: 15
Study 30452284 — intervention group
Group type: COMPARATOR
Intervention: MICex (Moderate-Intensity Continuous Exercise)
Number of subjects: 15
Study 30452284 — intervention group
Group type: COMPARATOR
Intervention: REST (Control)
Number of subjects: 15
Study 29629506 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based parenting program with group sessions and individualised home coaching
Number of subjects: 1447
Study 29629506 — intervention group
Group type: COMPARATOR
Intervention: Community-based parenting program without individualised home coaching
Number of subjects: 1447
Study 27157024 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 34
Study 27157024 — intervention group
Group type: COMPARATOR
Intervention: Online self-help intervention
Number of subjects: 34
Study 24919974 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-platelets
Number of subjects: 259
Study 24919974 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blockers
Number of subjects: 259
Study 24919974 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 259
Study 24919974 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
Number of subjects: 259
Study 24919974 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all four drug classes
Number of subjects: 259
Study 24919974 — intervention group
Group type: COMPARATOR
Intervention: Age ≥75 years
Number of subjects: 259
Study 24919974 — intervention group
Group type: COMPARATOR
Intervention: Ten or more visits with general practitioners (GPs) over 1 year
Number of subjects: 259
Study 24919974 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use at discharge
Number of subjects: 259
Study 21955873 — intervention group
Group type: EXPERIMENTAL
Intervention: SST (web-based support skills training)
Number of subjects: 40
Study 21955873 — intervention group
Group type: COMPARATOR
Intervention: HE (health education)
Number of subjects: 40
Study 19926841 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐PA
Number of subjects: 97
Study 19926841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 17416151 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at home and early discharge schemes
Number of subjects: 0
Study 15118827 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapsing-remitting multiple sclerosis (RRMS) patients
Number of subjects: 103
Study 15118827 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary progressive multiple sclerosis (SPMS) patients
Number of subjects: 103
Study 11590629 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-stage clinical trial design
Number of subjects: 21
Study 11590629 — intervention group
Group type: COMPARATOR
Intervention: Traditional randomized trial design
Number of subjects: 21
Study 9829873 — intervention group
Group type: EXPERIMENTAL
Intervention: Long questionnaire (76-item, 16-page)
Number of subjects: 0
Study 9829873 — intervention group
Group type: EXPERIMENTAL
Intervention: Short questionnaire (16-item, 4-page)
Number of subjects: 0
Study 9829873 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentive
Number of subjects: 0
Study 9829873 — intervention group
Group type: EXPERIMENTAL
Intervention: Second mailing of a questionnaire
Number of subjects: 0
Study 9829873 — intervention group
Group type: COMPARATOR
Intervention: Postcard reminder
Number of subjects: 0
Study 7858505 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐3‐7 arm (cytosine arabinoside 100 mg/m2 continuous infusion for 7 days and daunorubicin 50 mg/m2 IV day 1‐3 plus etoposide 75 mg/m2 IV days 1‐7)
Number of subjects: 264
Study 7858505 — intervention group
Group type: COMPARATOR
Intervention: 7‐3 arm (cytosine arabinoside 100 mg/m2 continuous infusion for 7 days and daunorubicin 50 mg/m2 IV day 1‐3)
Number of subjects: 264
Study 7858505 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 264
Study 2575630 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative bathing with chlorhexidine in 6 patients
Number of subjects: 15
Study 2575630 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chlorhexidine bathing)
Number of subjects: 15
Study 911218 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 40
Study 911218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclazocine
Number of subjects: 40
Study 911218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31049999 — intervention group
Group type: EXPERIMENTAL
Intervention: Unequal randomization designs
Number of subjects: 0
Study 31049999 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal allocation designs
Number of subjects: 0
Study 31049999 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted randomization procedures
Number of subjects: 0
Study 31049999 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical inference following randomization procedures
Number of subjects: 0
Study 31049999 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings from literature
Number of subjects: 0
Study 28096000 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glutamine oral care
Number of subjects: 88
Study 28096000 — intervention group
Group type: COMPARATOR
Intervention: 2% chlorhexidine gluconate solution oral care
Number of subjects: 88
Study 25452013 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual cervical distraction without visual feedback
Number of subjects: 48
Study 25452013 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual cervical distraction with visual feedback
Number of subjects: 48
Study 24119736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunoprophylaxis (200 IU HBIG and 5 or 10 mug yeast recombinant hepatitis B vaccine)
Number of subjects: 269
Study 24119736 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mug hepatitis B vaccine
Number of subjects: 269
Study 24119736 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mug hepatitis B vaccine
Number of subjects: 269
Study 24119736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined immunoprophylaxis (5 mug and 10 mug hepatitis B vaccine)
Number of subjects: 269
Study 21612742 — intervention group
Group type: COMPARATOR
Intervention: Propiverine hydrochloride (30 mg s.i.d.)
Number of subjects: 48
Study 21612742 — intervention group
Group type: COMPARATOR
Intervention: Propiverine hydrochloride (15 mg t.i.d.)
Number of subjects: 48
Study 19848050 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel milk
Number of subjects: 24
Study 16972810 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions intervention to plan overcoming barriers to attending mammography (specific barriers: changing appointment, arranging transport, negotiating time off work)
Number of subjects: 2082
Study 16972810 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only condition (completed a questionnaire about mammography)
Number of subjects: 2082
Study 16972810 — intervention group
Group type: COMPARATOR
Intervention: Nonassessment control condition (mere contact with the research team)
Number of subjects: 2082
Study 15381866 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI
Number of subjects: 25
Study 15381866 — intervention group
Group type: EXPERIMENTAL
Intervention: [15O]-H2O-PET
Number of subjects: 25
Study 15381866 — intervention group
Group type: COMPARATOR
Intervention: fMRI and [15O]-H2O-PET
Number of subjects: 25
Study 11257243 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal treatment during the 4th cycle
Number of subjects: 13
Study 11257243 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (3rd cycle) with Minulet and Econ/30
Number of subjects: 13
Study 9309267 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage antimony (20 mg/kg/day)
Number of subjects: 23
Study 9309267 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage antimony (5 mg/kg/day)
Number of subjects: 23
Study 9309267 — intervention group
Group type: COMPARATOR
Intervention: Both groups (5 mg/kg/day and 20 mg/kg/day)
Number of subjects: 23
Study 8214997 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 g/d gammalinolenic acid in borage seed oil
Number of subjects: 37
Study 8214997 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cotton seed oil)
Number of subjects: 37
Study 2894994 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol 100 mg b.d.
Number of subjects: 10
Study 2894994 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol 100 mg b.d.
Number of subjects: 10
Study 2894994 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol 200 mg b.d.
Number of subjects: 10
Study 2894994 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 10
Study 31707724 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus treatment (diet, monitoring, ± insulin)
Number of subjects: 5
Study 31707724 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (started early)
Number of subjects: 5
Study 31707724 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester hemoglobin A1c (5.9‐6.4%)
Number of subjects: 5
Study 31707724 — intervention group
Group type: EXPERIMENTAL
Intervention: First trimester hemoglobin A1c (5.7‐6.4%)
Number of subjects: 5
Study 30875151 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic cake (Bacillus coagulans) consumed for 1 week
Number of subjects: 40
Study 30875151 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cake consumed for 1 week
Number of subjects: 40